PDE4A and psoriasis: In psoriasis, apremilast confers a greater improvement of endothelial glycocalyx integrity, microvascular perfusion, arterial elasticity and LV myocardial function compared with etanercept or cyclosporine treatment, suggesting a favorable profile of PDE4 inhibition on cardiovascular function.